The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
 
Taylor Weiskittel
Employment - Actuate Therapeutics
Consulting or Advisory Role - Actuate Therapeutics
 
Austin Koukol
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
 
Caroline Kellinger
Employment - Actuate Therapeutics; Element Biosciences (I); Seascape Clinical
Stock and Other Ownership Interests - Element Biosciences (I); Seascape Clinical
Patents, Royalties, Other Intellectual Property - Patents related to sequencing via Element Biosciences: PLATFORM FOR DISCOVERY AND ANALYSIS OF THERAPEUTIC AGENTS; METHODS AND ARRAYS FOR PRODUCING AND SEQUENCING MONOCLONAL CLUSTERS OF NUCLEIC ACID; Compositions and methods for pairwise sequencing; Engine (I); Patents related to sequencing via Element Biosciences: PLATFORM FOR DISCOVERY AND ANALYSIS OF THERAPEUTIC AGENTS; METHODS AND ARRAYS FOR PRODUCING AND SEQUENCING MONOCLONAL CLUSTERS OF NUCLEIC ACID; Compositions and methods for pairwise sequencing; Engine (I)
 
Leiqing Zhang
No Relationships to Disclose
 
Benedito A. Carneiro
Consulting or Advisory Role - Seagen
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Repare Therapeutics (Inst)
 
Hu Li
Consulting or Advisory Role - Actuate Therapeutics; Cavalry Bioscience
 
Andrey Ugolkov
Employment - Curis
Stock and Other Ownership Interests - Actuate Therapeutics
Consulting or Advisory Role - Actuate Therapeutics
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences
 
Andrew Paul Mazar
Employment - Actuate Therapeutics
Leadership - Monopar Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics; Monopar Therapeutics
Patents, Royalties, Other Intellectual Property - UPAR patents Monopar, GSK-3 patents Actuate